Carregant...

Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis.

Fourteen patients with uraemic anaemia and having regular haemodialysis were given human recombinant erythropoietin in increasing doses, beginning with 24 U/kg thrice weekly. One patient was dropped from the study because of recurrent thrombosis of vascular access sites. In the other 13 patients, fo...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Casati, S, Passerini, P, Campise, M R, Graziani, G, Cesana, B, Perisic, M, Ponticelli, C
Format: Artigo
Idioma:Inglês
Publicat: 1987
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC1248067/
https://ncbi.nlm.nih.gov/pubmed/3120854
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!